• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Freeline Therapeutics Holdings plc (Amendment)

    1/31/23 4:15:02 PM ET
    $FRLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $FRLN alert in real time by email
    SC 13G/A 1 p23-0492sc13ga.htm FREELINE THERAPEUTICS HOLDINGS PLC

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     

    Freeline Therapeutics Holdings plc

    (Name of Issuer)
     

    Ordinary Shares, nominal value £0.00001 per share

    (Title of Class of Securities)
     

    35655L107**

    (CUSIP Number)
     

    December 31, 2022

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 9 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    ** The Ordinary Shares have no CUSIP number. The CUSIP number for the Company's American Depositary Shares, each representing one Ordinary Share, is 35655L107.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 35655L10713G/APage 2 of 9 Pages

     

    1

    NAME OF REPORTING PERSON

    Tetragon Financial Group Limited

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Guernsey

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,000,000

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,000,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,000,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.2%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

    CUSIP No. 35655L10713G/APage 3 of 9 Pages

     

     

     

    1

    NAME OF REPORTING PERSON

    Tetragon Financial Management L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,000,000

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,000,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,000,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.2%

    12

    TYPE OF REPORTING PERSON

    IA

             

     

    CUSIP No. 35655L10713G/APage 4 of 9 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Patrick G. G. Dear

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United Kingdom

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,000,000

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,000,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,000,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.2%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

    CUSIP No. 35655L10713G/APage 5 of 9 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Reade E. Griffith

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United Kingdom

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,000,000

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,000,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,000,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.2%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

    CUSIP No. 35655L10713G/APage 6 of 9 Pages

     

     

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Freeline Therapeutics Holdings plc (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, United Kingdom.

     

    Item 2(a). NAME OF PERSON FILING:

     

      This statement is filed by:

     

      (i)

    Tetragon Financial Group Limited ("Tetragon"), a Guernsey company, with respect to the Shares (as defined in Item 2(d)) represented by American Depositary Shares ("ADSs") directly and beneficially owned by it;

     

      (ii)

    Tetragon Financial Management L.P. ("Tetragon Manager"), a Delaware limited partnership, as the investment manager of Tetragon, with respect to the Shares represented by ADSs directly directly and beneficially owned by Tetragon;

     

      (iii)

    Patrick G. G. Dear ("Mr. Dear"), as principal to Tetragon Manager, with respect to the Shares represented by ADSs directly and beneficially owned by Tetragon; and

     

      (iv) Reade E. Griffith ("Mr. Griffith"), as principal to Tetragon Manager, with respect to the Shares represented by ADSs directly and beneficially owned by Tetragon.

     

      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares represented by ADSs reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

      The address of the principal office of each of Tetragon, Mr. Dear and Mr. Griffith is c/o Polygon Global Partners LLP, 4 Sloane Terrace, London SW1X 9DQ, United Kingdom. The address of the principal office of Tetragon Manager is 399 Park Avenue, 22nd Floor, New York, New York 10022.

     

     

    CUSIP No. 35655L10713G/APage 7 of 9 Pages

     

     

    Item 2(c). CITIZENSHIP:

     

      Tetragon is a company organized under the laws of Guernsey. Tetragon Manager is a Delaware limited partnership.  Messrs. Dear and Griffith are citizens of the United Kingdom.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Ordinary Shares, nominal value £0.00001 per share (the "Shares").

     

    Item 2(e). CUSIP NUMBER:
       
      The Ordinary Shares have no CUSIP number. The CUSIP number for the Company's American Depositary Shares, each representing one Ordinary Share, is 35655L107.

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

      (g) ¨

    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:                                                                                        

     

     

    CUSIP No. 35655L10713G/APage 8 of 9 Pages

     

     

    Item 4. OWNERSHIP:

     

      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
       
      The percentages used in this Schedule 13G/A are calculated based upon 64,974,850 Shares outstanding as of September 30, 2022, as reported in the Company's Report of Foreign Issuer on Form 6-K filed with the Securities and Exchange Commission on November 15, 2022.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:

     

      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:

     

      Not applicable.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON:

     

      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:

     

      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP:

     

      Not applicable.
       
    Item 10. CERTIFICATION:
       
       By signing below each of the undersigned certifies that, to the best of such person's knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 35655L10713G/APage 9 of 9 Pages

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned hereby certifies that the information set forth in this statement is true, complete and correct.
     
     
    DATE:  January 31, 2023
     
    TETRAGON FINANCIAL GROUP LIMITED
         
         
    By: /s/ Reade E. Griffith  
      Name:Reade E. Griffith  
      Title:Authorized Signatory  
         
         
    TETRAGON FINANCIAL MANAGEMENT L.P.
         
         
    By: /s/ Reade E. Griffith  
      Name:Reade E. Griffith  
      Title:Authorized Signatory  
         
         
    /s/ Patrick G.G. Dear  
    PATRICK G.G. DEAR  
         
         
    /s/ Reade E. Griffith  
    READE E. GRIFFITH  
         

     

    Get the next $FRLN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FRLN

    DatePrice TargetRatingAnalyst
    2/1/2022Overweight → Equal-Weight
    Morgan Stanley
    1/7/2022Neutral → Buy
    Redburn
    11/29/2021$10.00Buy
    BTIG
    8/18/2021$30.00 → $20.00Buy
    HC Wainwright & Co.
    8/17/2021$27.00 → $8.00Overweight → Neutral
    JP Morgan
    8/17/2021Overweight → Neutral
    JP Morgan
    More analyst ratings

    $FRLN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Freeline to Present New Data on its Gaucher and Parkinson's Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

      Late-breaking oral presentation on results from Phase 1/2 study of FLT201 in Gaucher disease Poster presentation to highlight Freeline's GBA1 Parkinson's disease research program LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics today announced the acceptance of multiple abstracts, including one for a late-breaking oral presentation on new clinical data from its Gaucher disease program, at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place May 7-11, 2024 in Baltimore, Maryland. "Gaucher disease is a severe and progressive disorder that leads to a wide range of symptoms, including enlarged organs, bone pain and fractures, low bl

      4/24/24 4:00:00 PM ET
      $FRLN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acquisition of Freeline by Syncona Becomes Effective

      LONDON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) ("Freeline") and Syncona Ltd ("Syncona") today announced that, in connection with Syncona's acquisition of Freeline by way of a scheme of arrangement (the "Scheme"), the Scheme has been sanctioned by the Court and the court order (together with a copy of the scheme circular published by Freeline on January 18, 2024 (the "Scheme Circular") has been delivered to the Registrar of Companies.   Accordingly, the Scheme has become Effective in accordance with its terms and the entire issued share capital of Freeline is now owned or controlled by Syncona Portfolio Limited. Capitalized terms in this an

      2/20/24 7:00:00 AM ET
      $FRLN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Freeline Shareholders Approve Acquisition by Syncona

      LONDON, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) ("Freeline") and Syncona Ltd ("Syncona") today announced that Freeline's shareholders have approved the proposal for Bidco 1354 Limited ("Bidco"), a wholly owned subsidiary of Syncona Portfolio Limited ("Syncona Portfolio"), to acquire all shares of Freeline not currently owned by Syncona Portfolio for $6.50 per American Depositary Share ("ADS") in cash (the "Acquisition"). As previously announced, Freeline and Bidco entered into an implementation agreement on November 22, 2023 to implement the Acquisition by means of a scheme of arrangement pursuant to Part 26 of the UK Companies Act 2006 (the "Sche

      2/12/24 12:00:00 PM ET
      $FRLN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FRLN
    Leadership Updates

    Live Leadership Updates

    See more
    • Genespire appoints Dr. Sabah Sallah as Chief Medical Officer

      Genespire appoints Dr. Sabah Sallah as Chief Medical Officer Accomplished executive with extensive preclinical and clinical gene therapy experience joins Genespire to accelerate pipeline to the clinic Milan, Italy, 7 July 2022: Genespire, a next generation gene therapy company developing first-in-class transformative therapies with advanced lentiviral vectors, today announces the appointment of Dr. Sabah Sallah MD, PhD as Chief Medical Officer. Dr. Sallah will lead the Company's clinical strategy, development and operations as Genespire progresses its novel advanced lentiviral gene therapy platforms towards the clinic. Dr. Sallah is a board-certified hematologist who has spent more than

      7/7/22 2:00:00 AM ET
      $FRLN
      $QURE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Freeline Appoints Paul Schneider as Chief Financial Officer

      LONDON, April 19, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) (the "Company" or "Freeline") today announced that Paul M. Schneider has been appointed Chief Financial Officer (CFO), effective May 16, 2022, based in Boston. Mr. Schneider joins Freeline from Exo Therapeutics, Inc., where he served as Senior Vice President, Finance and Operations. A seasoned financial executive with more than 20 years of leadership experience in large and small private and public biopharmaceutical companies, Mr. Schneider brings an impressive track record of financial stewardship, including corporate strategy and execution, financial planning, analysis and reporting, and investor

      4/19/22 8:01:00 AM ET
      $FRLN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Freeline Appoints Henning R. Stennicke, PhD, as Chief Scientific Officer to Lead Research and Discovery

      LONDON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) (the "Company" or "Freeline"), a clinical-stage biotechnology company developing transformative adeno-associated virus ("AAV") vector-mediated systemic gene therapies for people with inherited systemic debilitating diseases, today announced the expansion of its executive leadership team with the appointment of Henning R. Stennicke, PhD, as Chief Scientific Officer (CSO). Dr. Stennicke has been appointed to the role of CSO effective March 1, 2022. He will be based in Stevenage, UK, and report to Michael Parini, Freeline's Chief Executive Officer, as part of the executive leadership team. As CSO, Dr.

      2/3/22 7:00:00 AM ET
      $FRLN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FRLN
    Financials

    Live finance-specific insights

    See more
    • Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease

      Robust increases of up to 700-fold over baseline in plasma GCase enzyme activity in first two patients treated with FLT201 Normalization of leukocyte GCase in both patients demonstrates cellular uptake from plasma FLT201 has been well tolerated, with no serious adverse events Company to host conference call today at 8 a.m. ET LONDON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) today reported positive initial safety, tolerability and enzyme activity data from the ongoing Phase 1/2 GALILEO-1 trial evaluating FLT201, its adeno-associated virus (AAV) gene therapy candidate, in Gaucher disease. Gaucher disease is a debilitatin

      10/4/23 7:00:00 AM ET
      $FRLN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Freeline Reports Second Quarter 2023 Financial Results and Business Highlights

      Completed dosing in first cohort of Phase 1/2 GALILEO-1 trial of FLT201 in Gaucher disease; expect to report initial clinical data in third quarter of 2023 Extending impact of its novel GCase variant with research program for GBA1-linked Parkinson's disease Management to host conference call at 8:00 a.m. ET today LONDON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) today reported financial results for the second quarter of 2023 and provided a business update. "FLT201 is a potential first- and best-in-class gene therapy for Gaucher disease Type 1, the most common type of the disease," said Michael Parini, Chief Exec

      8/15/23 7:00:00 AM ET
      $FRLN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call

      LONDON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 15, 2023 to report its second quarter financial results and provide a corporate update. Participants may access this event via the teleconferencing numbers below and asking to join the Freeline call or through the webcast link here. Domestic: 1-866-524-3160International: 1-412-317-6760 While not required, it is recommended that participants join the call 10 minutes prior to the scheduled start. A live webcast of the call will also be available on the Investors section of Freeline's website at ww

      8/8/23 7:30:00 AM ET
      $FRLN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FRLN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Freeline Therapeutics Holdings plc (Amendment)

      SC 13D/A - Freeline Therapeutics Holdings plc (0001810031) (Subject)

      2/22/24 4:06:06 PM ET
      $FRLN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Freeline Therapeutics Holdings plc (Amendment)

      SC 13G/A - Freeline Therapeutics Holdings plc (0001810031) (Subject)

      2/14/24 12:15:26 PM ET
      $FRLN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Freeline Therapeutics Holdings plc (Amendment)

      SC 13G/A - Freeline Therapeutics Holdings plc (0001810031) (Subject)

      2/12/24 4:24:07 PM ET
      $FRLN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FRLN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Freeline Therapeutics downgraded by Morgan Stanley

      Morgan Stanley downgraded Freeline Therapeutics from Overweight to Equal-Weight

      2/1/22 7:44:12 AM ET
      $FRLN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Freeline Therapeutics upgraded by Redburn

      Redburn upgraded Freeline Therapeutics from Neutral to Buy

      1/7/22 7:43:23 AM ET
      $FRLN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BTIG initiated coverage on Freeline Therapeutics with a new price target

      BTIG initiated coverage of Freeline Therapeutics with a rating of Buy and set a new price target of $10.00

      11/29/21 7:17:07 AM ET
      $FRLN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FRLN
    SEC Filings

    See more
    • SEC Form 15-12G filed by Freeline Therapeutics Holdings plc

      15-12G - Freeline Therapeutics Holdings plc (0001810031) (Filer)

      3/1/24 4:05:32 PM ET
      $FRLN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Freeline Therapeutics Holdings plc

      EFFECT - Freeline Therapeutics Holdings plc (0001810031) (Filer)

      2/26/24 12:15:23 AM ET
      $FRLN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Freeline Therapeutics Holdings plc

      S-8 POS - Freeline Therapeutics Holdings plc (0001810031) (Filer)

      2/22/24 4:38:00 PM ET
      $FRLN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care